Journal of Clinical Pathways

Join us as Mariana Gouveia, MD, DASA Oncologia, gives an overview of the use of antibody-drug conjugates for the treatment of patients with endometrial cancer. #JournalOfClinicalPathways #dostarlimab #endometrialcancer #immunotherapy

We spoke with Jess Paulus, ScD, senior director of real-world research at Ontada, about trends in advanced non-small cell and small cell lung cancer diagnoses, the impact of the COVID-19 pandemic on screening, and the urgent need for improved access to preventive care and public health initiatives. "Lung cancer is a disease that's unfortunately been stigmatized at a lot of levels, including disparities and funding. As a society, we have to change this approach. For example, pink ribbon campaigns have been transformational for breast cancer research investment and moving the needle on survival. Lung cancer needs that ribbon. It needs that attention and investment," said Dr Paulus. Click here for the full interview: https://lnkd.in/e-dccrW5 #JournalOfClinicalPathways #LungCancer #NSCLC #NonSmallCellLungCancer #SmallCellLungCancer #CancerCare #CommunityOncology

A study presented at the 2024 ASCO Quality Care Symposium highlights gaps in palliative care access and education for patients with small cell lung cancer and their caregivers, emphasizing the urgent need for improved outreach and support in this vulnerable population. Read more about the survey here: https://lnkd.in/g-pWJ2vX #JournalofClinicalPathways #SCLC #CancerCare #PalliativeCare #LungCancer

In this interview, Federico Cappuzzo, MD, National Cancer Institute Regina Elena, Rome, Italy, discusses the benefits of the subcutaneous formulation of atezolizumab compared with atezolizumab intravenous. "The impact of subcutaneous atezolizumab on real-world practice will be very high because the possibility of delivering a drug in a very easy way is very important for the patient. It is extremely important because we need, particularly in cancer patients and particularly in patients with advanced disease, where the duration of life unfortunately is limited, we have to reduce the time they spend in the hospital." Check out the full video here: https://lnkd.in/e2zDAQVg #JournalOfClinicalPathways #CancerCare #ValueBasedCare #NonSmalCellLungCancer #LungCancer #NSCLC

A study published in Advances in Therapy in Therapy shows that momelotinib significantly improves anemia and related symptoms in patients with myelofibrosis, particularly those previously treated with ruxolitinib. Read more about the SIMPLIFY-2 trial here: https://lnkd.in/eeYC9S53 #JournalOfClinicalPathways #Myelofibrosis #Anemia #ValueBasedCare

Join us as a guest expert Edward R. Arrowsmith discusses the evolving role of clinical pathways in guiding treatment decisions for non-small cell lung cancer in the era of precision medicine and targeted therapies, emphasizing the importance of patient-focused care and continuous adaptation to changing treatment landscapes. #JournalOfClinicalPathways #NSCLC #cancercare #EGFR 

A study published in JAMA Oncology revealed that Black women are more likely to receive false negative results for endometrial cancer from transvaginal ultrasounds compared to their White counterparts. This discrepancy raises concerns about the effectiveness of current screening methods and the potential for delayed or missed diagnoses. Read more about the findings here: https://lnkd.in/e7xtWi27 #JournalOfClinicalPathways #EndometrialCancer #CancerCare #PreventativeCare #BlackWomen #CancerScreening

📢 Accepting Submissions Now! JCP publishes articles on topics including but not limited to:  • Real-world data, including patient-reported outcomes  • Comparative-effectiveness research  • The economics of implementing and utilizing clinical pathways  • Health economics and outcomes research  • Alternative payment and value-based care models Author Benefits  • No submission, article processing, or open-access fees for authors  • Expert review of your manuscript by thought leaders in the field  • Publication in our print edition and online multimedia platform, reaching an audience of 50,000 health care professionals nationwide Click here to read our FAQ: https://lnkd.in/eq7CRwfG

As employers finalize their 2025 health benefit plans, they're focusing on member enrollment and managing medical and pharmacy benefits amidst a changing health care landscape. Post-pandemic, employers must navigate economic pressures and competitive market shifts while considering multi-year financial risk trends for their covered populations. Key trends influencing these decisions: - Precision medicine is driving targeted care and better patient outcomes. - Whole person health emphasizes holistic care and cost management. - Biosimilars and biologics are transforming specialty care. - Rising Claim Costs highlight the need for transparency and careful planning. In the September/October issue for the Journal of Clinical Pathways, Randy Vogenberg, PhD details how employers must balance cost, quality, and consumer engagement to ensure sustainable health care coverage. #JournalofClinicalPathways #JCP #EmployerBenefits #HealthcareTrends #PrecisionMedicine #WholePersonHealth #Biosimilars #CostManagement #2025Planning https://lnkd.in/e6hYpiB3

Clinical pathways play a crucial role in standardizing cancer treatment, reducing care variation, and improving patient outcomes. While they are most widely adopted by sophisticated provider organizations and integrated delivery networks (IDNs), their potential to optimize oncology care is undeniable. Traditional management tools like formularies and order sets have been staples across various therapeutic areas, but in oncology, their impact is more immediate due to rapid advancements in precision medicine and new drug classes. Learn key insights on this topic from Lee Blansett, HMP Market Access Insights , by accessing his latest MAI Mindset: https://lnkd.in/ew8XsWjU #JournalofClinicalPathways #JCP #HMPMarketAccessInsights #MAI #Formularies #PrecisionMedicine